Tibet Rhodiola Pharmaceutical Holding Co Total Assets
Tibet Rhodiola Pharmaceutical Holding Co total assets. Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) holds total assets worth CN¥6.44 Billion CNY (≈ $942.30 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tibet Rhodiola Pharmaceutical Holding Co (600211) total market value for the company's overall valuation and market capitalisation.
Total Assets of Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)
Total assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025. This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's total assets have evolved over time, based on quarterly financial data. See 600211 live share price for real-time trading data and today's change.
Tibet Rhodiola Pharmaceutical Holding Co - Asset Composition Analysis
Tibet Rhodiola Pharmaceutical Holding Co Total Assets Breakdown (December 2025)
Tibet Rhodiola Pharmaceutical Holding Co total assets breakdown as of December 2025. Tibet Rhodiola Pharmaceutical Holding Co's total assets of CN¥6.44 Billion consist of 74.0% current assets and 26.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 26.6% |
| Accounts Receivable | CN¥989.61 Million | 15.8% |
| Inventory | CN¥181.27 Million | 2.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥302.12 Million | 4.8% |
| Goodwill | CN¥84.01 Million | 1.3% |
Asset Composition Trend (1996–2025)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 600211 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tibet Rhodiola Pharmaceutical Holding Co's current assets represent 74.0% of total assets in 2025, an increase from 48.4% in 1996.
- Cash Position: Cash and equivalents constituted 26.6% of total assets in 2025, up from 5.6% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 11.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 15.8% of total assets.
Tibet Rhodiola Pharmaceutical Holding Co Competitors by Total Assets
Key competitors of Tibet Rhodiola Pharmaceutical Holding Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Tibet Rhodiola Pharmaceutical Holding Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.87 | 2.94 | 1.97 |
| Quick Ratio | 2.76 | 2.83 | 1.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.19 Billion | CN¥2.78 Billion | CN¥836.32 Million |
Tibet Rhodiola Pharmaceutical Holding Co - Advanced Valuation Insights
This section examines the relationship between Tibet Rhodiola Pharmaceutical Holding Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.01 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | 32.0% |
| Total Assets | CN¥6.27 Billion |
| Market Capitalization | $1.90 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tibet Rhodiola Pharmaceutical Holding Co's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Tibet Rhodiola Pharmaceutical Holding Co's assets grew by 32.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)
The table below shows the annual total assets of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.27 Billion ≈ $917.12 Million |
+32.02% |
| 2024-12-31 | CN¥4.75 Billion ≈ $694.68 Million |
+3.49% |
| 2023-12-31 | CN¥4.59 Billion ≈ $671.27 Million |
+11.90% |
| 2022-12-31 | CN¥4.10 Billion ≈ $599.87 Million |
+7.80% |
| 2021-12-31 | CN¥3.80 Billion ≈ $556.45 Million |
+29.15% |
| 2020-12-31 | CN¥2.94 Billion ≈ $430.84 Million |
+6.40% |
| 2019-12-31 | CN¥2.77 Billion ≈ $404.93 Million |
+9.29% |
| 2018-12-31 | CN¥2.53 Billion ≈ $370.52 Million |
+8.67% |
| 2017-12-31 | CN¥2.33 Billion ≈ $340.96 Million |
+1.72% |
| 2016-12-31 | CN¥2.29 Billion ≈ $335.20 Million |
+224.31% |
| 2015-12-31 | CN¥706.33 Million ≈ $103.36 Million |
-32.50% |
| 2014-12-31 | CN¥1.05 Billion ≈ $153.13 Million |
-8.00% |
| 2013-12-31 | CN¥1.14 Billion ≈ $166.45 Million |
+34.59% |
| 2012-12-31 | CN¥845.15 Million ≈ $123.67 Million |
+7.27% |
| 2011-12-31 | CN¥787.86 Million ≈ $115.29 Million |
+7.12% |
| 2010-12-31 | CN¥735.47 Million ≈ $107.62 Million |
-1.11% |
| 2009-12-31 | CN¥743.70 Million ≈ $108.83 Million |
-10.36% |
| 2008-12-31 | CN¥829.66 Million ≈ $121.41 Million |
-0.28% |
| 2007-12-31 | CN¥831.96 Million ≈ $121.74 Million |
-4.03% |
| 2006-12-31 | CN¥866.90 Million ≈ $126.86 Million |
+5.64% |
| 2005-12-31 | CN¥820.62 Million ≈ $120.08 Million |
+5.58% |
| 2004-12-31 | CN¥777.25 Million ≈ $113.74 Million |
+3.04% |
| 2003-12-31 | CN¥754.36 Million ≈ $110.39 Million |
+2.90% |
| 2002-12-31 | CN¥733.08 Million ≈ $107.27 Million |
+20.51% |
| 2001-12-31 | CN¥608.33 Million ≈ $89.02 Million |
+15.13% |
| 2000-12-31 | CN¥528.36 Million ≈ $77.32 Million |
+21.06% |
| 1999-12-31 | CN¥436.44 Million ≈ $63.87 Million |
+152.78% |
| 1998-12-31 | CN¥172.66 Million ≈ $25.27 Million |
+44.29% |
| 1997-12-31 | CN¥119.66 Million ≈ $17.51 Million |
+153.66% |
| 1996-12-31 | CN¥47.18 Million ≈ $6.90 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more